Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Tixagevimab/Cilgavimab for Prevention of COVID-19 during the Omicron Surge: Retrospective Analysis of National VA Electronic Data

Yinong Young-Xu, Lauren Epstein, Vincent C Marconi, Victoria Davey, Gabrielle Zwain, Jeremy Smith, Caroline Korves, Fran Cunningham, Robert Bonomo, Adit A Ginde
doi: https://doi.org/10.1101/2022.05.28.22275716
Yinong Young-Xu
1White River Junction Veterans Affairs Medical Center, White River Junction, VT
2Geisel School of Medicine at Dartmouth, Hanover, NH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren Epstein
3Atlanta Veterans Affairs Medical Center, Decatur, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincent C Marconi
3Atlanta Veterans Affairs Medical Center, Decatur, GA
4Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victoria Davey
5US Department of Veteran’s Affairs, Office of Research and Development, Washington DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gabrielle Zwain
1White River Junction Veterans Affairs Medical Center, White River Junction, VT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremy Smith
1White River Junction Veterans Affairs Medical Center, White River Junction, VT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline Korves
1White River Junction Veterans Affairs Medical Center, White River Junction, VT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fran Cunningham
6US Department of Veterans Affairs, PBM, Center for Medication Safety, Hines, IL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Bonomo
7US Department of Veterans Affairs, VA SHIELD, Veterans Affairs Northeast Ohio Healthcare System, Cleveland, Ohio, USA
8Case Western Reserve University, Cleveland, Ohio, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adit A Ginde
9Department of Emergency Medicine, University of Colorado School of Medicine, Aurora. CO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: adit.ginde@cuanschutz.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background: Little is known regarding the effectiveness of tixagevimab/cilgavimab in preventing SARS-CoV-2 infection in this population, particularly after the emergence of the Omicron variant. Objective: To determine the effectiveness of tixagevimab/cilgavimab for prevention of SARS-CoV-2 infection and severe disease among immunocompromised patients. Design: Retrospective cohort study with propensity matching and difference-in-difference analyses. Setting: U.S. Department of Veterans Affairs (VA) healthcare system. Participants: Veterans age ≥18 years as of January 1, 2022, receiving VA healthcare. We compared a cohort of 1,848 patients treated with at least one dose of intramuscular tixagevimab/cilgavimab to matched controls selected from 251,756 patients who were on immunocompromised or otherwise at high risk for COVID-19. Patients were followed through April 30, 2022, or until death, whichever occurred earlier. Main Outcomes: Composite of SARS-CoV-2 infection, COVID-19-related hospitalization, and all-cause mortality. We used cox proportional hazards modelling to estimate the hazard ratios (HR) and 95% CI for the association between receipt of tixagevimab/cilgavimab and outcomes. Results: Most (69%) tixagevimab/cilgavimab recipients were ≥65 years old, 92% were identified as immunocompromised in electronic data, and 73% had ≥3 mRNA vaccine doses or two doses of Ad26.COV2. Compared to propensity-matched controls, tixagevimab/cilgavimab-treated patients had a lower incidence of the composite COVID-19 outcome (17/1733 [1.0%] vs 206/6354 [3.2%]; HR 0.31; 95%CI, 0.18-0.53), and individually SARS-CoV-2 infection (HR 0.34; 95%CI, 0.13-0.87), COVID-19 hospitalization (HR 0.13; 95%CI, 0.02-0.99), and all-cause mortality (HR 0.36; 95%CI, 0.18-0.73). Limitations: Confounding by indication and immortal time bias. Conclusions: Using national real-world data from predominantly vaccinated, immunocompromised Veterans, administration of tixagevimab/cilgavimab was associated with lower rates of SARS-CoV-2 infection, COVID-19 hospitalization, and all-cause mortality during the Omicron surge.

Competing Interest Statement

Funding Statement Supported by the Department of Veterans Affairs (VA) Office of Research and Development, the VA Office of Rural Health, Clinical Epidemiology Program at the White River Junction VA Medical Center, by resources and the use of facilities at the White River Junction VA Medical Center and VA Informatics and Computing Infrastructure, and data from the VA COVID-19 Shared Data Resource. Declaration of Authors Competing Interests VCM has received investigator-initiated research grants (to the institution) and consultation fees (both unrelated to the current work) from Eli Lilly, Bayer, Gilead Sciences and ViiV. YYX, GZ, CK, JS reported receiving grants from the US Food and Drug Administration through an interagency agreement with the Veterans Health Administration and from the US Department of Veterans Affairs Office of Rural Health. YYX, GZ, JS also reported receiving funding from Pfizer to US Department of Veterans Affairs for other research projects outside the submitted work. AAG received COVID-19 research project funding from the National Institutes of Health, Department of Defense, Centers for Disease Control and Prevention, AbbVie, and Faron Pharmaceuticals, outside the submitted work.

Funding Statement

Supported by the Department of Veterans Affairs (VA) Office of Research and Development, the VA Office of Rural Health, Clinical Epidemiology Program at the White River Junction VA Medical Center, by resources and the use of facilities at the White River Junction VA Medical Center and VA Informatics and Computing Infrastructure, and data from the VA COVID-19 Shared Data Resource.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the institutional review board of the VA Medical Center in White River Junction, Vermont, and was granted a waiver of informed consent because the study was deemed minimal risk and consent impractical to acquire.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data in the present work will not be made available.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 29, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Tixagevimab/Cilgavimab for Prevention of COVID-19 during the Omicron Surge: Retrospective Analysis of National VA Electronic Data
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Tixagevimab/Cilgavimab for Prevention of COVID-19 during the Omicron Surge: Retrospective Analysis of National VA Electronic Data
Yinong Young-Xu, Lauren Epstein, Vincent C Marconi, Victoria Davey, Gabrielle Zwain, Jeremy Smith, Caroline Korves, Fran Cunningham, Robert Bonomo, Adit A Ginde
medRxiv 2022.05.28.22275716; doi: https://doi.org/10.1101/2022.05.28.22275716
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Tixagevimab/Cilgavimab for Prevention of COVID-19 during the Omicron Surge: Retrospective Analysis of National VA Electronic Data
Yinong Young-Xu, Lauren Epstein, Vincent C Marconi, Victoria Davey, Gabrielle Zwain, Jeremy Smith, Caroline Korves, Fran Cunningham, Robert Bonomo, Adit A Ginde
medRxiv 2022.05.28.22275716; doi: https://doi.org/10.1101/2022.05.28.22275716

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (174)
  • Allergy and Immunology (420)
  • Anesthesia (97)
  • Cardiovascular Medicine (898)
  • Dentistry and Oral Medicine (169)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (405)
  • Epidemiology (8774)
  • Forensic Medicine (4)
  • Gastroenterology (404)
  • Genetic and Genomic Medicine (1858)
  • Geriatric Medicine (178)
  • Health Economics (387)
  • Health Informatics (1288)
  • Health Policy (644)
  • Health Systems and Quality Improvement (491)
  • Hematology (206)
  • HIV/AIDS (392)
  • Infectious Diseases (except HIV/AIDS) (10549)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1750)
  • Nursing (102)
  • Nutrition (265)
  • Obstetrics and Gynecology (342)
  • Occupational and Environmental Health (461)
  • Oncology (963)
  • Ophthalmology (281)
  • Orthopedics (107)
  • Otolaryngology (176)
  • Pain Medicine (117)
  • Palliative Medicine (41)
  • Pathology (263)
  • Pediatrics (556)
  • Pharmacology and Therapeutics (264)
  • Primary Care Research (218)
  • Psychiatry and Clinical Psychology (1842)
  • Public and Global Health (3977)
  • Radiology and Imaging (652)
  • Rehabilitation Medicine and Physical Therapy (343)
  • Respiratory Medicine (534)
  • Rheumatology (215)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (196)
  • Toxicology (37)
  • Transplantation (106)
  • Urology (80)